ArticleCost effectiveness and resource allocation : C/E2015

Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain.

Álvaro Hidalgo-Vega et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.